Aug. 14, 2025
| Today’s news and insights for biopharma leaders
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead of a debt maturity in 2027.
|
The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other companies like it.
|
UPDATED
Eight of the last 11 M&A deals and 17 of the 26 so far this year have involved public biotech companies, a reversal from last year when startups were more frequently the target of acquisitions.
|
Credit: Ben Fidler / BioPharma Dive
DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.
|
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
|
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
|
|
From Our Library
Trendline
Supported by Premier Inc
|
Webinar - on demand
Custom content for PurpleLab
|
Trendline
Supported by Marken
|
Playbook
Custom content for Cardinal Health
| |